Search Results

You are looking at 11 - 20 of 299 items for :

Clear All
Full access

Kenneth C. Anderson

“I believe not only that multiple myeloma will be a chronic illness, but also that we will see sustained complete responses in a significant fraction of patients,” predicted Kenneth C. Anderson, MD, as he described the emerging landscape in

Full access

Alessandra Larocca and Antonio Palumbo

Multiple myeloma (MM) is the second most common hematologic malignancy. It accounts for 1% of all cancers and 13% of hematologic neoplasms. The median age at diagnosis is 70 years, with 37% of patients younger than 65 years, 26% aged 65 to 74

Full access

Jorge J. Castillo

Numerous advances have recently been made in the treatment of relapsed/refractory (R/R) multiple myeloma (MM): novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have

Full access

Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jorge Castillo, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Yubin Kang, Adetola Kassim, Michaela Liedtke, Ehsan Malek, Thomas Martin, Vishala T. Neppalli, James Omel, Noopur Raje, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Donna Weber, Joachim Yahalom, Rashmi Kumar and Dorothy A. Shead

for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma NCCN Guidelines Insights : Multiple Myeloma, Version 3.2018 Version 3.2018 © National Comprehensive

Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar

activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma

Full access

Kenneth C. Anderson

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma contain 2 important updates that should translate into more effective treatment with available agents. However, what is particularly exciting to Kenneth C

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M. Vose, Donna Weber, Joachim Yahalom and Furhan Yunus

the express written permission of the NCCN © 2009. Disclosures for the NCCN Multiple Myeloma Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry

Full access

Ashley T. Freeman, May Kuo, Lei Zhou, Justin G. Trogdon, Chris D. Baggett, Sascha A. Tuchman, Thomas C. Shea and William A. Wood

–outcome relationship in multiple myeloma (MM) showing that patients treated at low-volume facilities had a 22% increased risk of death compared with those treated at high-volume facilities. Provider expertise and hospital volume are overlapping, but both these distinct

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch and Alfred I. Neugut

Multiple myeloma (MM) is a hematologic malignancy characterized by significant bone disease; lytic lesions are present in >60% of patients at diagnosis, as are pathologic fractures, osteoporosis, and hypercalcemia. 1 Due to the frequency and

Full access

Ashraf Badros

Multiple myeloma (MM) is a clinically and pathophysiologically heterogeneous disease, as evidenced by variable response to treatment and variation in survival from a few months to more than 10 years. Nationwide U.S. data show that approximately 20